HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016
Summary
Acute Market Reports, ‘HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016’, provides in depth analysis on HIV-1 Integrase (EC 2.7.7.) targeted pipeline therapeutics.
Browse Full Report Visit - http://www.acutemarketreports.com/report/hiv-1-integrase-ec-277-pipeline-review-h1-2016
The report provides comprehensive information on the HIV-1 Integrase (EC 2.7.7.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics development and features dormant and discontinued projects.
Acute Market Reportsreport features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Acute Market Reports proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Browse All Reports of This Category - http://www.acutemarketreports.com/category/healthcare-market
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for HIV-1 Integrase (EC 2.7.7.)
- The report reviews HIV-1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects
- The report assesses HIV-1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to HIV-1 Integrase (EC 2.7.7.) targeted therapeutics
- The report reviews HIV-1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects
- The report assesses HIV-1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to HIV-1 Integrase (EC 2.7.7.) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for HIV-1 Integrase (EC 2.7.7.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HIV-1 Integrase (EC 2.7.7.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for HIV-1 Integrase (EC 2.7.7.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HIV-1 Integrase (EC 2.7.7.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Get Complete Report @ HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Acute Market Reports Coverage 6
HIV-1 Integrase (EC 2.7.7.) Overview 7
Therapeutics Development 8
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Stage of Development 8
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Therapy Area 9
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Indication 10
HIV-1 Integrase (EC 2.7.7.) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Companies 13
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Universities/Institutes 15
HIV-1 Integrase (EC 2.7.7.) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
HIV-1 Integrase (EC 2.7.7.) - Companies Involved in Therapeutics Development 23
Critical Outcome Technologies Inc. 23
Gilead Sciences, Inc. 24
Merck & Co., Inc. 25
TGV-Laboratories 26
ViiV Healthcare Limited 27
HIV-1 Integrase (EC 2.7.7.) - Drug Profiles 28
(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(dolutegravir sodium + rilpivirine hydrochloride) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
cabotegravir sodium - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Acute Market Reports Coverage 6
HIV-1 Integrase (EC 2.7.7.) Overview 7
Therapeutics Development 8
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Stage of Development 8
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Therapy Area 9
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Indication 10
HIV-1 Integrase (EC 2.7.7.) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Companies 13
HIV-1 Integrase (EC 2.7.7.) - Products under Development by Universities/Institutes 15
HIV-1 Integrase (EC 2.7.7.) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
HIV-1 Integrase (EC 2.7.7.) - Companies Involved in Therapeutics Development 23
Critical Outcome Technologies Inc. 23
Gilead Sciences, Inc. 24
Merck & Co., Inc. 25
TGV-Laboratories 26
ViiV Healthcare Limited 27
HIV-1 Integrase (EC 2.7.7.) - Drug Profiles 28
(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(dolutegravir sodium + rilpivirine hydrochloride) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
cabotegravir sodium - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Latest Reports :
About - Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us :
Chris Paul
ACUTE MARKET REPORTS
Office No 101, 1st Floor ,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
India: +91 7755981103
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
Contact Us :
Chris Paul
ACUTE MARKET REPORTS
Office No 101, 1st Floor ,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
India: +91 7755981103
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
